Articles from Atelerix

Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced a partnership with Frontier Space, a UK based space biotechnology company building platform technology for in-orbit R&D and biomanufacturing. Under the two-year memorandum of understanding (MoU), the companies will validate Atelerix’s alginate hydrogel encapsulation technology for preserving biological samples during microgravity research missions, improving sample quality and reducing payload mass and associated costs.

Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced the launch of STORganoid™, an ambient-temperature preservation solution for organoids and spheroids. The product enables storage and shipment of complex 3D cell models over extended periods of time, without compromising viability or reproducibility.

Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has established a strategic partnership with JH Health Ltd, a Saudi Arabian company focused on medical and health-related technology. The partnership grants JH Health exclusive rights to use and distribute Atelerix’s hydrogel-based cell and tissue preservation solutions in the Middle East, significantly bolstering Atelerix’s global commercial footprint with new regional manufacturing and distribution channels.

Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has entered a partnership with Cherry Biotech, a French company specialising in organ-on-chip and organoid technologies for biomedical research.

Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced an agreement with Labskin, a global leader in laboratory-grown human skin models used for research, testing and product development. The partnership follows a series of successful shipping trials, demonstrating Atelerix’s non-cryogenic preservation technology is able to maintain the structural integrity and viability of Labskin’s 3D constructs well beyond the traditional 72–96-hour transport window.

Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced an agreement with Rodon Global (“Rodon”), the established freight company focused on clinical trials and drug discovery headquartered in South Africa. The collaboration comes at a pivotal time as Rodon actively expands operations across the United States, UK, South Africa, and Singapore. By integrating Atelerix’s unique cryo-free preservation products within Rodon’s dynamic logistics offering, the collaboration will significantly broaden access to safe shipping and storage solutions for temperature-sensitive biomaterials, without freezing.